Bristol-Myers Squibb Company (NYSE:BMY) SVP Joseph C. Caldarella sold 9,340 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $560,400.00. Following the completion of the transaction, the senior vice president now directly owns 46,297 shares in the company, valued at $2,777,820. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Bristol-Myers Squibb Company (NYSE:BMY) traded down 0.35% on Friday, hitting $62.62. The stock had a trading volume of 6,579,310 shares. Bristol-Myers Squibb Company has a 1-year low of $46.01 and a 1-year high of $63.47. The company’s 50 day moving average is $57.32 and its 200-day moving average is $55.65. The firm has a market capitalization of $102.69 billion, a price-to-earnings ratio of 22.87 and a beta of 1.18.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.01. The firm had revenue of $5.14 billion for the quarter, compared to analysts’ expectations of $5.09 billion. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The company’s revenue was up 5.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.69 earnings per share. On average, analysts forecast that Bristol-Myers Squibb Company will post $2.98 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/09/08/bristol-myers-squibb-company-bmy-svp-joseph-c-caldarella-sells-9340-shares.html.

Several research analysts have recently commented on the company. BidaskClub raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Saturday, August 12th. Credit Suisse Group reissued a “hold” rating on shares of Bristol-Myers Squibb in a report on Friday. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and issued a $63.00 target price on shares of Bristol-Myers Squibb in a report on Wednesday, August 9th. Vetr downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $64.20 target price on the stock. in a report on Thursday. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $66.00 target price (up from $63.00) on shares of Bristol-Myers Squibb in a report on Thursday, August 24th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and ten have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $62.54.

Large investors have recently modified their holdings of the company. Toronto Dominion Bank lifted its holdings in shares of Bristol-Myers Squibb by 54.0% during the first quarter. Toronto Dominion Bank now owns 464,591 shares of the biopharmaceutical company’s stock worth $25,264,000 after purchasing an additional 162,884 shares during the period. Mutual of America Capital Management LLC lifted its holdings in shares of Bristol-Myers Squibb by 1.9% during the first quarter. Mutual of America Capital Management LLC now owns 201,037 shares of the biopharmaceutical company’s stock worth $10,932,000 after purchasing an additional 3,833 shares during the period. Meridian Management Co. lifted its holdings in shares of Bristol-Myers Squibb by 1.5% during the first quarter. Meridian Management Co. now owns 51,770 shares of the biopharmaceutical company’s stock worth $2,815,000 after purchasing an additional 770 shares during the period. Atria Investments LLC lifted its holdings in shares of Bristol-Myers Squibb by 15.1% during the first quarter. Atria Investments LLC now owns 40,861 shares of the biopharmaceutical company’s stock worth $2,222,000 after purchasing an additional 5,349 shares during the period. Finally, HPM Partners LLC acquired a new position in shares of Bristol-Myers Squibb during the first quarter worth $2,400,000. Institutional investors own 68.80% of the company’s stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Insider Buying and Selling by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.